Treating depression with different galenical drug formulations: Does it make a difference? The comparison of mirtazapine fast dissolving formulation (FDT) with conventional mirtazapine tablets (CT)

International Journal of Psychiatry in Clinical Practice

Volumn 13, Issue 2, 2009, Pages 109-116

  Delini Stula, Alexandra ^a,c   Van Oers, Helga ^b   Van Willigenburg, Arjen ^b   Oddens, Bjorn ^b   Schutte, Albert Jan ^b   Van Der Meulen, Egbert ^b  

^a ADI International Institute for Advancement of Drug Development   (Switzerland)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ADI International Institute for Advancement of Drug Development   (Switzerland)

Author keywords

Antidepressants; Compliance; Fast dissolving tablets (FDT); Internet based survey technology; Mirtazapine; Weight gain

Indexed keywords

MIRTAZAPINE;

ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DEPRESSION; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG FORMULATION; FAST DISSOLVING FORMULATION; FEMALE; GALENICAL DRUG FORMULATION; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; TABLET FORMULATION; TASTE; WEIGHT GAIN;

EID: 67249134483     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500802485262     Document Type: Article

References (29)

1. Demyttenaere K. Risk factors and predictors of compliance in depression. Eur Neuropsychopharmacol 2003;13(Suppl 3):S69-75. (Pubitemid 37188777)
2. Behnke K, Sogaard I, Martin S, Bäuml J, Ravindran A, Agren H, Vester-Blokand E. Mirtazapine orally disintegrating tablet versus sertraline: A Prospective onset of action study. I Clin Psychopharmacol 2003;23:358-364. (Pubitemid 36951177)
3. Roose S Multi-site, open-label, observational study of the effectiveness and safety of mirtazapine orally disintegrating tablets in depressed patients who were at least 50 years of age. Presented at the 15th Annual Meeting of the American Association of Geriatric Psychiatry; 24-27 February 2002, Orlando, Florida
4. Delini-Stula A, Bischof R. The results of the Swiss observational study of the new, fast-dissolving mirtazapine formulation in depressed patients. J Psychiatr Clin Pract 2007;10(2):124-130
5. De Haan L, Van Amelsvoort T, Rosien K, Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004;175:389-390 (Pubitemid 39361928)
6. Stip E, Anselmo K, Wolfe M, Lessard C, Landry P. Long-term treatment with atypical antipsychotics and risk of weight gain. Drug Saf 2006;29:550-552 (Pubitemid 43855087)
7. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;61(Suppl 11):37-41. (Pubitemid 30616693)
8. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand 1997;96(Suppl 391):31-37
9. Kuyper LM, Wood E, Montaner JS, Yip B, O'Connell JM, Hogg RS. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-infected patients in a population-based cohort. J AIDS 2004;37(4):1470-1476 (Pubitemid 39602337)
10. Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med 2004;19(11):1111-1117 (Pubitemid 39552581)
11. Lee R, Taira DA. Adherence to oral hypoglycemic agents in Hawaii. Prev Chronic Dis 2005;2(2):A09.
12. Corda RS, Burke HB, Horowitz HW. Adherence to prescription medications among medical professionals. South Med J 2000;93(6):585-589 (Pubitemid 34263230)
13. Van Oers HJJ, Simmons JH, Van Willigenburg APP. Global preference survey shows that patients prefer fast dissolving tablets and compliance improves with this novel formulation. Int J Neuropsychopharmacol 2006;9(Suppl 1):S83.
14. Simansky KJ. Serotonergic control of the organization of feeding and satiety. Behav Brain Res 1996;73:37-42. (Pubitemid 26008760)
15. Den Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995;10(Suppl 4):19-23. (Pubitemid 26058317)
16. CIMA Labs INC. Internal report. CIMA Labs Inc, Brooklyn Park, Minnesota, 2002.
17. Delini-Stula A, Bischof R, Desax A Antidepressant efficacy and patient acceptance of a new formulation of Mirtazapine (Remeron SolTab®) in depressed patients in practice. Eur J Neurpsychopharmacol (Abstr ECNP Congress, 9-13 October, Stockholm, Sweden, 2004.
18. Hong CJ, Hu WH, Chen CC, Hsiao CC, Tsai SJ, Ruwe FJ. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 2003;64(8):921-926 (Pubitemid 37022758)
19. Zhang JS, Liu TQ, Hao W, Xie GR, SU LY, Yue WH. Control study of mirtazapine and fluoxetine in therapy of depression. Zhongguo Linchuang Kangfu 2003;7:4102-4104 (Pubitemid 38636659)
20. Frijlink HW. Benefits of different drug formulations in psychopharmacology. Eur Neuropsychopharmacol 2003;13(Suppl 3):S77-84.
21. Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery - a review. Pharm Sci Technolo Today 2000;3(4):138 = 145. (Pubitemid 30195827)
22. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. J Am Med Assoc 2002;288(22):2880-2883 (Pubitemid 35425074)
23. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. J Am Med Assoc 2002;288(22):2868-2879 (Pubitemid 35425073)
24. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150(9):1881-1884 (Pubitemid 20316533)
25. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, Ilersich AL. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002;24(2):302-316
26. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296-1310 (Pubitemid 32804122)
27. Balon R, Arfken CL, Mufti R. Patients' preferences about medication dosing regimens. Psychiatr Serv 1998;49(8):1095. (Pubitemid 28363838)
28. Viale G. An economic analysis of physician prescribing of selective serotonin reuptake inhibitors. Hosp Pharm 1998;33:847-850
29. Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM. An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey. J Affect Disord 2006;90(2-3):217-221 (Pubitemid 43183531)